Drug intelligence / Profile preview

bms-986020

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986020 is an orally administered small molecule that acts as a selective antagonist of lysophosphatidic acid receptor 1 (LPA1). It was developed as an antifibrotic agent for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The drug inhibits LPA1-mediated signaling pathways involved in fibrogenesis and extracellular matrix remodeling. In clinical studies, BMS-986020 demonstrated reduction in serum biomarkers associated with fibrosis and showed efficacy in animal models of fibrosis. The compound reached phase II clinical trials but development for IPF and psoriasis has been discontinued[1][3][4][6].

Other names: AP-3152 free acidAP3152 free acidAP 3152 free acid38CTP01B4L

Targets

LPAR1 (Lysophosphatidic acid receptor 1)

Beyond the preview

Go deeper on bms-986020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bms-986020.

Explore the full profile